文献速递银屑病与炎症性皮肤病

替拉珠单抗治疗中重度银屑病148周长期疗效与安全性:两项III期试验汇总分析

Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
PubMed 文献 · Br J Dermatol · 2019-07-18

本文汇总reSURFACE 1和reSURFACE 2两项双盲随机对照试验,评估替拉珠单抗100mg与200mg治疗中重度斑块状银屑病至148周的长期疗效与安全性。第148周时,初始应答者维持较高PASI应答率,部分应答者换用200mg后疗效改善,不良事件发生率低。

要点

  • 替拉珠单抗100mg和200mg应答者在148周内维持高PASI 75/90/100应答。
  • 对依那西普部分应答或无应答者换用替拉珠单抗200mg后疗效改善。
  • 替拉珠单抗长期安全性良好,严重不良事件发生率低。

核心结论

  • 替拉珠单抗耐受性良好,第28周应答者持续治疗至3年疗效维持良好。
  • 依那西普部分应答或无应答者换用替拉珠单抗后疗效改善。

研究设计与样本

  • 汇总分析两项双盲随机对照试验reSURFACE 1和reSURFACE 2。
  • 评估替拉珠单抗100mg和200mg每12周给药至148周的疗效与安全性。
  • 缺失数据采用无应答者填补、多重填补和观察病例三种方法。

临床怎么用

  • 替拉珠单抗100mg或200mg可用于中重度斑块状银屑病长期治疗。
  • 对依那西普应答不佳者,换用替拉珠单抗200mg可能改善疗效。
  • 长期治疗需关注严重感染、恶性肿瘤和心血管事件等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tildrakizumab is a specific anti-interleukin-23p19 monoclonal antibody approved for the treatment of plaque psoriasis. OBJECTIVES: To evaluate the long-term efficacy and safety of tildrakizumab treatment for patients with moderate-to-severe psoriasis for up to 148 weeks. METHODS: Pooled analysis from two double-blind, randomized controlled trials: reSURFACE 1 and reSURFACE 2. Efficacy was assessed for responders (≥ 75% improvement in Psoriasis Area and Severity Index; PASI 75) and partial responders (PASI 50-75) to tildrakizumab 100 mg and 200 mg at week 28 who were maintained on the same dose (administered every 12 weeks), and for partial responders or nonresponders (PASI < 50) to etanercept 50 mg at week 28 who, after a 4-week washout, were switched to tildrakizumab 200 mg (administered at weeks 32 and 36, and every 12 weeks thereafter). Safety was assessed in the all-patients-as-treated population. Three different methods of imputing missing data were used: nonresponder imputation (NRI), multiple imputation and observed cases. The Clinicaltrials.gov numbers are NCT01722331 (reSURFACE 1) and NCT01729754 (reSURFACE 2). RESULTS: At week 148 (NRI), 72·6%, 53·8% and 28·9% of tildrakizumab 100-mg responders and 80·2%, 59·9% and 32·6% of tildrakizumab 200-mg responders had PASI 75, 90 and 100 responses, respectively. For partial responders to tildrakizumab 100 mg and 200 mg, the proportions of patients achieving PASI 75, 90 and 100 responses were 32·5%, 25·0% and 10·0%; and 47·1%, 27·5% and 12·8%, respectively. For patients who were partial responders or nonresponders to etanercept, the proportions of patients achieving PASI 75, 90 and 100 responses were 66·9%, 43·8% and 14·9% at week 148. Rates of discontinuations due to adverse events [tildrakizumab 100 mg: 1·7 per 100 patient-years (PYs); tildrakizumab 200 mg: 1·2 per 100 PYs] and exposure-adjusted rates of serious adverse events (5·9 per 100 PYs; 5·5 per 100 PYs), severe infections (1·1 per 100 PYs; 1·1 per 100 PYs), malignancies (0·6 per 100 PYs; 0·4 per 100 PYs) and major adverse cardiovascular events (0·4 per 100 PYs; 0·5 per 100 PYs) were low. CONCLUSIONS: Tildrakizumab was well tolerated and efficacy was well maintained in week 28 responders who continued tildrakizumab treatment through 3 years, or improved among etanercept partial responders or nonresponders who switched to tildrakizumab. What's already known about this topic? Tildrakizumab 100 mg and 200 mg are efficacious and well tolerated with short-term use in the treatment of patients with moderate-to-severe plaque psoriasis. What does this study add? High levels of efficacy are maintained for up to 3 years of psoriasis treatment with tildrakizumab. There is a favourable long-term safety profile with both tildrakizumab 100 mg and 200 mg, with a low incidence of adverse events of special interest through 3 years.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2019. PMID: 31218661. doi:10.1111/bjd.18232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。